Crescent Biopharma (CBIO) Return on Sales (2013 - 2026)

Crescent Biopharma (CBIO) has 10 years of Return on Sales data on file, last reported at 0.22% in Q1 2026.

• Quarterly Return on Sales changed N/A year-over-year to 0.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.54% (changed N/A YoY) and the FY2025 annual result came in at 0.14%, changed N/A from the prior year.
• Return on Sales grew to 0.22% in Q1 2026 per CBIO's latest filing, from 5.51% in the prior quarter.
• Across five years, Return on Sales topped out at 0.22% in Q1 2026 and bottomed at 5.51% in Q4 2024.
• The 3-year median for Return on Sales is 3.01% (2022), against an average of 3.11%.
• Peak annual rise in Return on Sales reached 101226 bps in 2022, while the deepest fall reached 100 bps in 2022.
• Tracing CBIO's Return on Sales over 3 years: stood at 5.04% in 2022, then fell by 9 bps to 5.51% in 2024, then surged by 96 bps to 0.22% in 2026.
• Per Business Quant, the three latest CBIO Return on Sales figures stand at 0.22% (Q1 2026), 5.51% (Q4 2024), and 5.04% (Q4 2022).

Peer Comparison